ESC Congress 2022 Barcelona

Important sex-related differences in heart failure exist. For example, women are drastically over-represented among patients with heart failure with preserved ejection fraction. This is particularly important as no medication classes have been shown to reduce cardiovascular or all-cause mortality in heart failure with preserved ejection fraction. In addition, women are also more likely than men to present with and die from cardiogenic shock after acute myocardial infarction. Furthermore, certain cardiomyopathies are specific to women (peripartum cardiomyopathy) or affect predominantly women (takotsubo syndrome).

CHAIRPERSONS:

Marco Roffi (University Hospital of Geneva – Geneva, Switzerland)
Carolyn Sp Lam (Duke-NUS Graduate Medical School Singapore – Singapore, Singapore)
Barbara Casadei (John Radcliffe Hospital – Oxford, United Kingdom of Great Britain & Northern Ireland)

LOCATION:

Fira de Barcelona Gran Via
Barcelona, Spain
Location: Room Dali

DATE & TIME:

Monday, August 29, 2022
8:30 am – 10:00 am

LEARNING OBJECTIVES:

Attendees will learn about sex- and gender-specific aspects of pathophysiology and risk factors for heart failure with a special focus on the role of social determinants of health. In addition, this session will inform about sex- and gender-based disparities in treatment and diagnosis of heart failure in women and how to address these in daily clinical practice. A special focus will lay on cardiomyopathies specific to or predominant in women.

AGENDA

Welcome remarks
Speaker: Carolyn SP Lam (Duke-NUS Graduate Medical School Singapore – Singapore, Singapore)
Time: 08:30

Global burden of cardiovascular disease in women: why does it matter?
Speaker: Marco Roffi (University Hospital of Geneva – Geneva, Switzerland)
Time: 08:35

Heart failure with reduced ejection fraction – sex-related aspects in pathophysiology, diagnosis, and pharmacological treatment

Speaker: Ileana Pina (Thomas Jefferson University – Philadelphia, United States of America)

Time: 08:40

New strategies for detection, prevention, and treatment of heart failure with preserved ejection fraction
Speaker: Giuseppe M C Rosano (St Georges Medical School – London, United Kingdom of Great Britain & Northern Ireland)

Time: 08:55

Enrollment of women heart failure trials – progress made, innovative next steps

Speaker: Carolyn SP Lam (Duke-NUS Graduate Medical School Singapore – Singapore, Singapore)
Time: 09:10

Sex-related issues for device therapies in chronic heart failure: update on current evidence and new innovations in interventional HF trials
Speaker: Javed Butler (The University of Mississippi Medical Center – Jackson, United States of America)
Time: 09:25

Cardiomyopathies in women: Takotsubo syndrome, peripartum cardiomyopathy, and cardiogenic shock

Speaker: Clara Ines Saldarriaga (Cardiovascular Clinic Santa Maria – Medellin, Colombia)

Time: 09:40

The Lancet Women and Cardiovascular Disease Commission: heart failure in women – what every clinician needs to know – closing remarks

Speaker: Roxana Mehran (Icahn School of Medicine at Mount Sinai – New York, United States of America)
Time: 09:55

The Lancet Women and Cardiovascular Disease Commission: heart failure in women – what every clinician needs to know – panel of experts
Discussant: Roxana Mehran (Icahn School of Medicine at Mount Sinai – New York, United States of America)
Discussant: Monica Acevedo (Facultad de Medicina, Pontificia Universidad Catolica de Chile – Santiago, Chile)
Discussant: Angela Maas (Isala Hospital – Zwolle, Netherlands (The))
Discussant: Agnieszka Olszanecka (Jagiellonian University, Medical College – Krakow, Poland)
Discussant: Mayra Guerrero (Mayo Clinic – Rochester, United States of America)
Discussant: C Noel Bairey Merz (Cedars-Sinai Smidt Heart Institute – Los Angeles, United States of America)
Discussant: Anastasia Mihailidou (Royal North Shore Hospital – Sydney, Australia)

COMMISSIONERS